HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial by Mariette I E van Poelgeest et al.
van Poelgeest et al. Journal of Translational Medicine 2013, 11:88
http://www.translational-medicine.com/content/11/1/88RESEARCH Open AccessHPV16 synthetic long peptide (HPV16-SLP)
vaccination therapy of patients with advanced or
recurrent HPV16-induced gynecological
carcinoma, a phase II trial
Mariette I E van Poelgeest1†, Marij J P Welters2†, Edith M G van Esch1, Linda F M Stynenbosch2, Gijs Kerpershoek1,
Els L van Persijn van Meerten3, Muriel van den Hende1, Margriet J G Löwik1, Dorien M A Berends-van der Meer1,
Lorraine M Fathers4, A Rob P M Valentijn4, Jaap Oostendorp4, Gert Jan Fleuren5, Cornelis J M Melief6,7,
Gemma G Kenter1,8† and Sjoerd H van der Burg2*†Abstract
Background: Human papilloma virus type 16 (HPV16)-induced gynecological cancers, in particular cervical cancers,
are found in many women worldwide. The HPV16 encoded oncoproteins E6 and E7 are tumor-specific targets for
the adaptive immune system permitting the development of an HPV16-synthetic long peptide (SLP) vaccine with
an excellent treatment profile in animal models. Here, we determined the toxicity, safety, immunogenicity and
efficacy of the HPV16 SLP vaccine in patients with advanced or recurrent HPV16-induced gynecological carcinoma.
Methods: Patients with HPV16-positive advanced or recurrent gynecological carcinoma (n = 20) were
subcutaneously vaccinated with an HPV16-SLP vaccine consisting of a mix of 13 HPV16 E6 and HPV16 E7
overlapping long peptides in Montanide ISA-51 adjuvant. The primary endpoints were safety, toxicity and tumor
regression as determined by RECIST. In addition, the vaccine-induced T-cell response was assessed by proliferation
and associated cytokine production as well as IFNγ-ELISPOT.
Results: No systemic toxicity beyond CTCAE grade II was observed. In a few patients transient flu-like symptoms
were observed. In 9 out of 16 tested patients vaccine-induced HPV16-specific proliferative responses were detected
which were associated with the production of IFNγ, TNFα, IL-5 and/or IL-10. ELISPOT analysis revealed a vaccine-
induced immune response in 11 of the 13 tested patients. The capacity to respond to the vaccine was positively
correlated to the patient’s immune status as reflected by their response to common recall antigens at the start of
the trial. Median survival was 12.6 ± 9.1 months. No regression of tumors was observed among the 12 evaluable
patients. Nineteen patients died of progressive disease.
Conclusions: The HPV16-SLP vaccine was well tolerated and induced a broad IFNγ-associated T-cell response in
patients with advanced or recurrent HPV16-induced gynecological carcinoma but neither induced tumor regression
nor prevented progressive disease. We, therefore, plan to use this vaccine in combination with chemotherapy and
immunomodulation.
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The causal role of Human Papillomavirus (HPV) infec-
tions in the development of gynecological cancers, in
particular cervical intraepithelial neoplasia and cervical
carcinoma, has been unambiguously established. Whereas
at an early-stage cervical cancer has a low risk of recur-
rence after treatment (15%), the more advanced cancers
(FIGO stages IIB/III/IV) display a risk of up to 70% for
recurrence [1-4]. Genital infections with high-risk HPV
are very common and the virus is mainly acquired through
sexual activity [5-7]. Genital HPV infection is highly
prevalent in young sexually active individuals. In the ma-
jority of infected subjects the infection is cleared within
one year [8,9]. However, infection with the high-risk HPV
type 16 (HPV16) is associated with a greater risk for dis-
ease progression and HPV16 is the most common type in
patients with invasive cervical cancer [10,11]. HPV16 en-
codes the two tumor-specific oncoproteins E6 and E7 that
can elicit a favorable immune response, in which virus-
specific interferon-γ (IFNγ)-producing CD4+ cells and
CD8+ cytotoxic T-lymphocytes (CTL) are able to control
and eliminate virus-infected cells [12,13]. However, in case
of an uncontrolled persistent infection with a high-risk
type HPV, the expression of the viral oncoproteins E6 and
E7 contributes to the development of cervical (pre)malig-
nancies. Apparently, the immune system fails to respond
adequately in these patients and this correlates with
the absence or weak expansion or activation of HPV16-
specific CD4+ and CD8+ T cells in such patients [14-18].
Importantly, the presence of HPV16-specific responses,
albeit weak, is associated with prolonged survival in pa-
tients with deeply invading tumors [19].
The treatment of advanced cervical cancer consists of
platinum-based chemotherapy but, with a response rate of
20% to 30%, is seldom curative and should be considered
as palliative treatment. This is reflected in a poor median
survival time in these patients; fewer than 20% survive one
year [20-22]. Attempts to improve the treatment-strategy
by the use of several chemotherapeutics simultaneously
had sporadically resulted in higher response rates and a
short increase in overall survival [20,23]. A recent phase
III trial of four cisplatin-containing doublet combinations
in patients with a stage IVB, recurrent or persistent cer-
vical carcinoma showed no statistically significant dif-
ferences in survival, albeit that a trend in response rate
favored the use of cisplatin and paclitaxel [24]. Clearly,
there is a great medical need to identify novel treatment
strategies for patients with cervical cancer, particularly for
patients in the higher risk categories (e.g. patients classified
as stage IIB or higher).
Recently, we developed a highly immunogenic syn-
thetic long peptide (SLP) vaccine, consisting of long
overlapping peptides of the E6 and E7 oncogenic pro-
teins of HPV16 with an excellent treatment profile inanimal models [25-28]. Clinical testing of this vaccine in
patients with cervical cancer showed that it harbored the
capacity to elicit strong and broad HPV16-specific CD4+
and CD8+ T-cell responses in most of the patients.
Furthermore, it revealed that the vaccine’s toxicity was
not beyond grade 2 and well tolerated by the patients
[29,30]. Treatment of patients with HPV16-positive high-
grade vulvar intraepithelial neoplasia (VIN3) with this
vaccine resulted in clinical responses including complete
regressions [31]. Notably, clinical outcome was correlated
with the strength of the vaccine-induced HPV16-specific
T-cell response [32]. We here report the results of our
study in which the HPV16-SLP vaccine was tested not
only for its safety and tolerability but also for its cap-
acity to induce HPV16-specific T-cell responses and
clinical responses in patients with advanced or recur-
rent HPV16-induced gynecological carcinoma.
Methods
Patients and vaccination
This was a phase II trial with the objective to determine
the immunological and clinical response to immunother-
apy with long peptides derived from the HPV16 E6 and
E7 protein in patients with a HPV16-induced advanced
or recurrent gynecological carcinoma as well as to assess
the safety and tolerability of this type of vaccination.
The study was approved by the medical ethical commit-
tee of the Leiden University Medical Center (P05.086).
Vaccine and treatment scheme
The vaccine consisted of a mix of 13 overlapping 25-35
-mer peptides representing the entire sequence of the E6
and E7 proteins of HPV16 (HPV16-SLP) dissolved in
dimethylsulfoxide (DMSO) and admixed with 20 mM
phosphate buffer (pH 7.5) and the adjuvant Montanide
ISA-51. The vaccine was produced at the GMP facility of
the Leiden University Medical Center (LUMC) [29,31].
The vaccine has been administered at a dose of 300 μg
per peptide by subcutaneous injection. Vaccinations were
carried out maximally 4 times, at different sites, with a
3-weeks interval. All vaccinations were administered to
the patients at the LUMC.
Eligibility criteria
Eligibility requires all of the following criteria: a) Men-
tally competent patients of 18 years and older, b) Clinical
and radiological evidence of recurrent gynecological can-
cer, with measurable lesions (preferably histopathologic-
ally confirmed), c) No curative treatment (surgery or
radiotherapy) options, d) HPV16 positive tumor, e) Per-
formance status of WHO 1–2 or Karnofsky-score >60, f)
Pre-treatment laboratory findings of white blood cells
(WBC) > 3,000 × 10 9/l, lymphocytes > 1,000 × 10 9/l,
platelets > 100 × 10 9/l, hematocrit > 30%, g) No indication
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and/or HBV infection), h) No history of autoimmune dis-
ease or systemic intercurrent disease which might affect
immunocompetence, i) No history of a second malignancy
except curatively treated low-stage tumors with a histology
that can be differentiated from the gynecological cancer
type, j) No radiotherapy, chemotherapy or other potentially
immunosuppressive therapy administered within 4 weeks
prior to immunotherapy, k) Life expectance of more than
6 months.
Examinations
Prior to each vaccination the patient was subjected to
physical examination and evaluated for performance sta-
tus, weight, Hb, hematocrit, WBC differential platelets,
PT and PTT, serum creatinine, Na, K, bilirubine, AF,
gamma GT, ASAT, ALAT and LDH. Additionally after
second and fourth vaccination a gynecological examin-
ation was performed.
Follow up was performed every 3 months during the first
two years by history taking, physical and gynecological
examination. Imaging techniques (multidetector CT- or
MRI scan) were performed 6–8 weeks after the last vaccin-
ation or earlier when clinically relevant.
Definition and measurement of tumor lesions
Tumor load was assessed using Response Evaluation
Criteria in Solid Tumors, version 1.0 (RECIST 1.0).
Measurable disease was defined as the presence of at
least one measurable lesion. If measurable disease was
restricted to a solitary lesion, its neoplastic nature was
confirmed by cytology/histology. A lesion was consid-
ered measurable, if accurate measurement of the longest
diameter was ≥10 mm on CT or MRI.
Non-measurable lesions were defined as all other le-
sions, including small lesions (<10 mm on CT or MRI),
bone lesions and cystic lesions, and non-measurable dis-
ease, such as leptomeningeal disease, ascites, pleural/
pericardial effusion, inflammatory breast disease, lymph-
angitis cutis/pulmonis.
Target lesions, defined as all measurable lesions up to
a maximum of five lesions per organ and 10 lesions in
total, representative of all involved organs were identi-
fied, recorded and measured at baseline. Target lesions
were selected on the basis of their size (lesions with the
longest diameter) and their suitability for accurate re-
peated measurements (either by imaging techniques or
clinically). A sum of the longest diameter (LD) for all
target lesions was calculated and reported as the baseline
sum LD. The baseline sum LD was used as reference to
determine an objective tumor response by comparing
this to sum LD of target lesions after therapy. Non-
target lesions comprise all other lesions (or sites of dis-
ease) of which the presence was recorded at baselineand throughout follow-up. All baseline evaluations were
performed as closely as possible to the beginning of
treatment and never earlier than 4 weeks before the be-
ginning of the treatment.
Evaluation of tumor response
The primary endpoint of the study was an objective
tumor response. The evaluation of responses was based
on RECIST 1.0. The overall response covered both the
response of target and non-target lesions.
A complete response (CR) was defined as disappear-
ance of all target lesions. A partial response (PR) was de-
fined as at least a 30% decrease in the sum of the LD of
target lesions when compared to the baseline sum LD.
Progressive disease (PD) was defined as at least a 20%
increase in the sum of the LD of target lesions in com-
parison with the lowest sum of the LD of target lesions
(i.e. nadir, best result) or the appearance of one or more
new lesions. Stable disease (SD) is defined as neither a
sufficient shrinkage to qualify for PR nor sufficient in-
crease to qualify for PD. For the non-target lesions CR
indicated disappearance of all non-target lesions. PR/SD
indicated persistence of one or more non-target lesion(s).
PD is defined as appearance of one or more new lesions
and/or unequivocal progression of existing non-target
lesions.
All radiological assessments were performed by a sin-
gle experienced radiologist (ELvPvM).
Evaluation of safety and tolerability
Adverse events, injection site reactions and clinical la-
boratory variables were monitored and scored according
to the CTCAE version 3. Injection site reactions were
defined as swelling, erythema and tenderness. All pa-
tients were examined physically before every vaccination
and medical history was taken. Vital sign examination
was performed after each vaccination and patients were
given a diary to mark all events in the first week after
each vaccination.
Evaluation of the HPV16-specific T-cell response to
vaccination
In acknowledgement to the “minimal information about
T cell assays (MIATA)” framework detailed information
is given provided about the sample, assay, data acquisi-
tion, data analysis, laboratory environment [33].
The sample: Peripheral blood mononuclear cells (PBMC)
before, after the second and after the fourth vaccination
were isolated within 6 hours after blood was drawn,
using Ficoll density gradient centrifugation and con-
trolled cryopreserved (Cryosolution) in 90% fetal calf
serum (PAA laboratories, Pasching, Austria) and 10%
dimethylsulphoxide (Sigma, St Louis, MO, USA). Equal
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phase of the liquid nitrogen vessel until use [34].
The assay, data acquisition and analysis: PBMC were
tested for HPV16-specificity by a set of complementary
T-cell immune monitoring assays, including lymphocyte
proliferation assay (LST), cytokine bead array (CBA) and
IFN-γ-ELISPOT in which cells were stimulated with
pools of 22 amino acid long peptides, overlapping by 12
amino acids. All tests have previously been described.
Positive and vaccine-induced responses were pre-defined
[29,32]. Briefly, antigen-specific T-cell responses were
determined in each blood sample by a short-time pro-
liferation assay according to Standard Operating Pro-
cedure (SOP). Freshly isolated PBMC were incubated
in 8-replicate wells in medium with 10% autologous
serum in the presence of the indicated antigens. On
day 6, supernatant was harvested for cytokine analysis
and the cells pulsed overnight with [3H]Thymidine.
The mean plus 3 times standard deviation (STD) of the
8 medium control wells was used as cut-off value. The
stimulation index (SI) was calculated by dividing the
mean of tested wells by the mean of the medium con-
trol. A positive proliferative response was defined as a
SI of ≥3 provided that the counts of ≥6 out of 8-wells
were above the cut-off value. The supernatants isolated
on day 6 of the proliferation assay were subjected to a
Th1/Th2 inflammation cytometric bead array (CBA) kit
(BD Biosciences, Erembodegem, Belgium) according to
the instructions of the manufacturer. The cut-off value
was 20 pg/ml, except for IFNγ, for which this was
100 pg/ml. Antigen-specific cytokine production was
positive when above the cut-off value and at least twice
the medium control. An interferon-γ (IFNγ) ELISPOT
assay was performed if at least one blood sample was
available after 2 vaccinations. PBMC isolated before
and after 2 and/or 4 vaccinations were tested to quan-
tify the number of IFNγ-producing HPV-specific T cells
according to SOP. Spots were counted with a fully auto-
mated computer-assisted-video-imaging analysis system
(BioSys 5000). Specific spots per 100.000 PBMC were cal-
culated by subtracting the mean number of spots + 2 times
the standard deviation (STD) of the medium only control
from the mean number of spots in experimental wells.
Antigen-specific T-cell frequencies were considered to
be increased compared to non-responders when specific
T-cell frequencies were ≥ 1/10.000. A vaccine-induced
response was defined as at least a 3-fold increase in the
response after vaccination when compared to the base-
line sample.
The laboratory environment: The T-cell assays were
performed in the laboratory of the department of Clinical
Oncology (LUMC, Leiden) that operates under research
conditions. Standard operating procedure (SOPs), includ-
ing predefined criteria for positive responses, were appliedby trained personnel. This laboratory has participated
in all proficiency panels of the CIMT Immunoguiding
Program (http://www.cimt.eu/workgroups/cip/), as well
as in IFNγ ELISPOT panels of the Cancer Immuno-
therapy Consortium, which aim is to harmonize the
reporting and assays used for T-cell monitoring [33,35].Statistical analysis
Comparisons of the strength of the different types of im-
mune responses were made by analyzing the differences
between the groups of patients with a lower or equal ver-
sus a higher median survival (12.6 months whole group
and 8.8 months for cervical cancer patients only) by the
non-parametric Mann–Whitney test using GraphPad
InStat Software. For each different type of immune
assay the strength was defined as the median specific
spot count (ELISPOT), SI (LST) or amount of cytokine
production (CBA) obtained for all 6 different peptide
pools per patient, of all patients in one group. In order
to assess whether the responsiveness to MRM at base-
line was associated with the response to HPV after vac-
cination by each patient the Fishers Exact test was used.
All reported p-values are 2-sided and have not been
adjusted for multiple comparisons. A p-value ≤0.05 was
considered to indicate statistical significance. Statistical
comparisons of different parameters between the group
of vaccinated cervical cancer patients and a matched
cohort were performed using IBM SPSS20 statistics.
Kaplan-Meier curves were used to illustrate the survival
of the two groups. Paired Wilcoxon signed rank test
and a Log Rank (Mantel Cox) test were used to deter-
mine the differences in survival between the matched
control cohort and vaccinated patients.Results
Patients & Vaccinations
Fifty-five patients with advanced or recurrent gynecological
carcinoma were screened between May 2006 and April
2010. Thirty-two were HPV16-positive of which 21
could be recruited for this study. The other HPV16-
positive patients refused to participate (n = 4), displayed
progressive disease (n = 4) or did not fulfill the inclusion
criteria (n = 3). Within the enrolled patient group, 2 pa-
tients displayed a HPV16-induced vaginal carcinoma
(ID 7, 9), 2 patients a HPV16-induced anal carcinoma
(ID 10, 21), and 17 patients a HPV16-induced cervical
carcinoma. The mean age at inclusion was 46.8 years
(STD 9.3; range 30–63). Patient characteristics are listed
in Table 1.
Of the 21 included patients, 1 patient died of progressive
disease before start of the vaccinations (ID 18). Eleven pa-
tients completed all 4 vaccinations (ID 1, 8–11, 13, 14, 17,
19–21). Five patients received three vaccinations (ID 2–4,
Table 1 Patient characteristics
ID Age Primary tumor Recurrence
Diagnosis Recurrence Inclusion Type FIGO
stage







1 40 41 41 cervix IB1 RH/CHRT Cisplatin LR 14 12.0
2 49 51 51 cervix IIB CHRT Cisplatin D 26 33.3
3 43 46 46 cervix IB1 RH/RT D 37
4 34 35 36 cervix IB2 CHRT/RH Cisplatin D 18 17.1
5 30 30 30 cervix IB1 RH/CHRT Cisplatin LR 6 5.3
6 55 56 56 cervix IIIB CHRT UK D 3 3.9
7 51 52 53 vagina IVB CHRT Carboplatin/
Taxol
D 16 RT 19.6
8 34 36 36 cervix IB1 RH/RT D 19 CH Cisplatin/
Topotecan
1.8
9 54 56 56 vagina IIB CHRT Cisplatin D 20 RT + HT 22.9
10 38 45 46 anus CHRT UK LR 79 CHRT UK 41.9
11 44 46 46 cervix IIIB CHRT Cisplatin D 6 4.9
12 36 40 41 cervix IIA RH/CHRT Cisplatin D 40 HT + CH Carboplatin/
Taxol
4.4
13 62 63 63 cervix IV RH/CHRT Cisplatin D 11 7.9
14 32 32 32 cervix IIB CHRT Cisplatin D 8 7.5
15 35 36 36 cervix IB1 SN/CHRT Cisplatin LR 4 SUR 4.3
16 54 54 54 cervix IV
17 48 49 50 cervix IIB SUR D 9
18 58 59 59 cervix IB2 CHRT/RH Cisplatin D 11 RT
19 52 54 54 cervix IIA CHRT Carboplatin/
Cisplatin
LR 31 37.4
20 39 40 41 cervix IB1 RH D 14 CHRT + CH Carboplatin/
Taxol
2.2
21 46 47 47 anus CH Cisplatin/
Vinorelbine
4 6.5
LR, locoregional; D, distant metastasis; RH, radical hysterectomy; CH, chemotherapy; CHRT, chemoradiation; RT, radiotherapy; SN, Sentinal Node Procedure; HT,
hyperthermia; SUR, surgery; UK, unknown; FIGO, International Federation of Gynecologists and Obstetricians. FIGO stage IB1 (clinical lesion ≤ 4 cm) and IB2 (clinical
lesion > 4 cm) confined to the cervix. Stage II: tumor extension beyond the cervix, but not the distal 1/3 part of the vagina or the pelvic wall (stage IIA:
involvement of the proximal 2/3 part of the vagina, stage IIB: parametrial involvement). Stage IIIB, carcinoma has extended to the pelvic wall and/or the distal 1/3
part of the vagina, and/or causes hydronefrosis. Stage IV, carcinomas spread to the mucosa of the bladder or rectum (stage IV A) or distant organs (stage IVB). The
interval between the primary tumor and recurrence (prim-rec) is given in months. The interval between the chemotherapy and the 1st vaccination (Chemo-1st
Vac) was calculated by using the starting date of the last given chemotherapy and the date of first vaccination as reference points.
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and 16; Table 2).
Safety and tolerability
Tumor progression was the main reason for early ter-
mination in the study. All patient deaths occurred due
to progressive disease. One patient stopped after 3 vacci-
nations because of persisting flu-like symptoms and
swelling of vaccination sites (ID 2). Overall, the vaccine
was well tolerated. None of the systemic and local ad-
verse events exceeded CTCAE grade 2 (Table 3). The
vaccination was accompanied mostly with erythema and
swelling of the skin (Table 4). Hematological valuesassessed in the blood samples drawn before and after
vaccination did not show significant changes (Wilcoxon
signed rank test; not shown).
Tumor response and survival
The last follow-up was performed in December 2011. In
11 of the 20 vaccinated patients target lesions were identi-
fied and measured before and after vaccination (Table 2).
In 8 patients post-vaccination scans were not made be-
cause of refusal to undergo radiological examinations
(ID 20) or because of clinically progressive disease or
death. In 3 patients, the target lesions displayed stable dis-
ease (SD) while the target lesions of all other 8 patients
Table 2 Patient vaccination and outcome





























1 4 died 9 8.1 120 161 PD PD
2 3 RT died 21 6.4 52 70 PD PD
3 3 CH + RT Cisplatin/Topotecan 1.9 died 19 2.4 132 138 SD PD
4 3 died 8 4.8 149 189 PD PD
5 2 died 6 1.8 68 89 PD PD
6 2 died 4
7 2 CH Carboplatin/
Gemcitabin
1.0 died 13 6.2 NE NE NE NE
8 4 CHRT/SUR Carboplatin/Taxol 4.2 died 26 5.5 31 61 PD PD
9 4 CH Cisplatin/Topotecan 4.0 died 26 3.9 67 67 SD PD
10 4 died 25 4.7 68 88 PD PD
11 4 died 7
12 3 died 15
13 4 died 5 3.6 87 80 SD PD
14 4 died 7 1.3 112 151 PD PD
15 3 died 8 3.5 0 0 PD
16 2 died 7
17 4 CH Cisplatin/Topotecan 2.1 UK 20
18 0 died 4
19 4 died 15
20 4 died 37
21 4 died 12 4.7 63 79 PD PD
CH, chemotherapy; CHRT, chemoradiation; LD, longest diameter; NE, not evaluable; PD, progressive disease; RT, radiotherapy; SD, stable disease, SUR, surgery. The
interval between the 1st vaccination and the chemotherapy after the vaccinations (1st Vac-Chemo) was calculated by using the date of first vaccination and the
starting date of the given chemotherapy during/after the vaccinations as reference points.
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vaccinated patients non-target lesions could be evaluated.
The overall tumor response in all 12 patients in whom a
response could be assessed, was progressive disease.
After immunotherapy, 3 patients were treated with che-
motherapy only, 2 patient with chemo-radiation therapy
and one patient with radiotherapy only. In December
2011, the median overall survival of the vaccinated group
(n = 20) was 12.6 months (STD 9.1; range 4–26 months)
after diagnosis of recurrence and 27.3 months (STD 23.8;
range 7–56 months) after primary diagnosis. Recalculation
of the survival for the 16 vaccinated patients with HPV16-
induced cervical carcinoma revealed a median overall sur-
vival of 8.8 months (STD 9.2; range 4–37 months) after
diagnosis of recurrence and 24.5 months (STD 18.2; range
7–56) after primary diagnosis. One patient (ID 20) was
alive in a clinically good condition at 19.4 months after
4 vaccinations (December 2011), she came back withprogressive disease in May 2012 but was still alive in
October 2012.
Immune responses
Blood samples were isolated from 20 patients before vac-
cination and from 15 patients after the second vaccin-
ation, from 11 of whom blood was also isolated after
either the third or fourth vaccination. In 9 patients a
vaccine-induced HPV16-specific proliferative response
after the second and/or last vaccination was found. A
significant increase in the strength of proliferation was
noted after either 2 vaccinations and after 3 to 4 vacci-
nations (p < 0.0001, Mann Whitney) compared to base-
line values. Furthermore, the strength of the response
increased between 2 vaccine doses and the last vac-
cination (p = 0.008, Mann Whitney) (Figure 1). Detailed
data is provided in an additional table (Additional file 1).
No significant differences were found in the strength of
Table 3 Systemic and local adverse events in 20 patients who received at least one vaccination
Patients (N = 20) Vaccinations (N = 67)
CTCAE grade 1 CTCAE grade 2 CTCAE grade 3 CTCAE grade 1 CTCAE grade 2 CTCAE grade 3
<24 h >24 h total <24 h >24 h total <24 h >24 h total <24 h >24 h total <24 h >24 h total <24 h >24 h total
Systemic adverse events
Fever 6 (30%) 1 (5%) 5 (25%) 2 (10%) 1 (5%) 3 (15%) - - - 7 (10.5%) 1 (1.5%) 7 (10.5%) 3 (4.5%) 1 (1.5%) 4 (6%) - - -
Chills/rigors 6 (30%) 1 (5%) 6 (30%) - - - - - - 10 (15%) 1 (1.5%) 11 (16.5%) - - - - - -
Myalgia (yes/no) 0 (0%) 1 (5%) 1 (5%) - - - - - - 0 (0%) 1 (1.5%) 1 (1.5%) - - - - - -
Fatigue 0 (0%) 1 (5%) 1 (5%) 2 (10%) 3 (15%) 3 (15%) - - - 1 (1.5%) 4 (6%) 3 (4.5%) 4 (6%) 4 (6%) 6 (9%) - - -
Nausea 6 (30%) 2 (10%) 6 (30%) - - - - - - 7 (10.5%) 3 (4.5%) 9 (13.5%) - - - - - -
Vomiting 2 (10%) 1 (5%) 2 (10%) - - - - - - 2 (3%) 2 (3%) 3 (4.5%) - - - - - -
Headache - - - 1 (5%) 2 (10%) 2 (10%) - - - 1 (1.5%) 1 (1.5%) 1 (1.5%) 2 (3%) 3 (4.5%) 3 (4.5%) - - -
Rash/Generalised erythema 3 (15%) 1 (5%) 3 (15%) 1 (5%) - 1 (4%) - - - 5 (7.5%) 1 (1.5) 5 (7.5%) 1 (1.5%) - 1 (1.5%) - - -
Inability to concentrate (Y/N) - - - - - - - - - 0 (0%) 0 (0%) 0 (0%) - - - - - -
Tingling extremities 1 (5%) 2 (10%) 2 (10%) - - - - - - 1 (1.5%) 0 (0%) 1 (1.5%) - - - - - -
Swelling extremities 2 (10%) 2 (10%) 4 (20%) - - - - - - 3 (4.5%) 2 (3%) 5 (7.5%) - - - - - -
Flu-like symptoms/Malaise 4 (20%) 3 (15%) 7 (35%) - - - - - - 5 (7.5%) 5 (7.5%) 10 (15%) - - - - - -
Local adverse events
Injection site reaction 0 (0%) 20 (100%) 0 (0%) 0 (0%) 67 (100%) 0(0%)


















Table 4 Injection site reactions in 20 patients who
received at least one vaccination






















All the injection sites were scored 1 hour after administration of the vaccine.
The pain and itching is scored at the following visit (i.e. 3 weeks after the
vaccination by using the diary). Only the maximal injection site reaction per
patient is scored.
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(MRM) when the reactivity between the pre-vaccination
blood sample and that of the second or last vaccination,
shown in an additional figure (Additional file 2) were
compared, indicating that the increase in HPV16-
specific T-cell reactivity was vaccine-mediated.
Analysis of the cytokines produced in the lymphocyte
stimulation test (LST) upon stimulation with the HPV16
peptide pools revealed the production of IFNγ in 7 patients
(0–4845 pg/ml) and IL-5 in 11 patients (0–1602 pg/ml).
Low amounts of TNFα were detected in 6 patients
(0–796 pg/ml) and that of IL-10 in 11 patients (0–196 pg/
ml). In 4 cases all 4 cytokines were detected (ID 1, 10, 19
and 20), in 1 case (ID21) only IL-5 and IL-10 was detected
and in 1 case (ID 8) only IL-10 was detected. There was a
significant increase in the level of IFNγ and IL-5 produc-
tion after the second and after the last vaccination
(Figure 1). This was also observed for TNFα and IL-10.
The strength of the cytokine response increased between
the second and last vaccination, although this was only
significant for IL-5 (Figure 1). For none of these cytokinesa significant increase in the response to the mix of recall
antigens (MRM) after any of the vaccinations was ob-
served (Additional file 2), indicating that the increase
in HPV-specific cytokine production was induced by
vaccination.
An HPV16-specific vaccine-induced IFNγ-associated
immune response as measured by IFNγ-ELISPOT was
detected in 12 of the 13 evaluable patients and possibly
in 15 patients, as for 3 patients the pre-vaccination sam-
ple was not evaluable or not available, shown in an add-
itional table (Additional file 3). There was a significant
increase in the strength of the frequency of IFNγ produ-
cing T cells as measured by IFNγ-ELISPOT after the sec-
ond and after the last vaccination (p < 0.0001, Mann
Whitney). There was no significant increase in the
strength of the response between the second and last
vaccination (Figure 1). As expected, no statistical signifi-
cant differences were found in reactivity to MRM in the
samples isolated before and after vaccination (Additional
file 2). Of note, the non-statistical significant small in-
creases in cytokine production or number of spots upon
stimulation with MRM seen after 3–4 vaccinations prob-
ably is due to the underrepresentation of patients who
performed poorly as they often did not receive more
than 2 vaccinations and responded also less to vaccin-
ation (see below). Comparison of the results from the
analysis of IFNγ secreted by T cells during proliferation
with that of the IFNγ-ELISPOT assay showed no dis-
crepancies with respect to the detection of positive re-
sponses, albeit that the IFNγ-ELISPOT assay detected
HPV-specific IFNγ production in an additional 5 cases
(ID 8, 12, 15, 17, 21).
We then assessed whether the capacity of the patients
to respond to the HPV16-SLP vaccine was associated
with their general immune status at the start of the trial.
Analysis of the data set of 16 patients tested for HPV16-
specific reactivity by LST and/or IFNγ-ELISPOT re-
vealed that of the 6 patients who lacked a MRM-specific
immune response at the start, 3 responded to the vac-
cine as detected by either one of the two assays whereas
3 did not. All of the 10 patients who displayed MRM-
specific reactivity at the start of the trial also mounted
an HPV-specific response after vaccination (p = 0.04) as
detected by either one of the two assays. A similar ob-
servation was made when the responsiveness as mea-
sured by proliferation was analyzed, albeit that this was
not significant (p = 0.06).
Comparison of overall survival with HPV-specific T-cell
reactivity
The median survival of this group of patients (n = 20)
was 12.6 months. Therefore, the group of patients was
divided into a cohort of patients with an overall survival




































































































































Figure 1 Vaccination results in stronger HPV16-specific immune responses. The strength (median + interquartile range) of the indicated
immune response to all 6 pools of HPV16 E6 and E7 peptides for the whole group measured before vaccination (pre-vac), after 2 vaccinations
(2-vac) and after the 3rd or 4th vaccination (3/4-vac) is given. Only when the strength of the immune response was significantly different, this is
indicated by the p-value. Measured was the vaccine-induced proliferation as indicated by the stimulation index using the lymphocyte stimulation
test, the antigen-specific increase in the numbers of IFNγ-producing T cells by ELISPOT, and the antigen-specific production of cytokines (IFNγ,
IL-5, TNFα and IL-10) in the supernatant of the lymphocyte stimulation test detected by cytokine bead array.
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a significant increase in the strength of HPV16-specific
proliferation or number of HPV16-specific T cells as mea-
sured by IFNγ-ELISPOT after the second and after the last
vaccination (Figure 2). However, the patients that lived
longer displayed a significantly stronger immune response
after the second and/or the last vaccination than the pa-
tients with a relative short survival, and this was reflected
in all assays (Figure 2). Detailed data is provided in an add-
itional table (Additional file 4). There was no significant
difference in HPV-specific reactivity between the groups
before they were vaccinated nor was there a difference be-
tween the groups in their reactivity to MRM at all time
points tested.We then assessed the relationship between HPV16-
specific immune reactivity and the survival within the
group of patients with a cervical carcinoma only. The
median survival was 8.8 months and the patients were
divided into two groups accordingly (Additional file 5).
Not enough patients were tested by IFNγ-ELISPOT so
that the analysis was limited to the results of the LST
and associated cytokine production. The HPV-16-spe-
cific proliferation was weak and on average below the
cut-off of the proliferation assay (SI >3) for the group of
patient with a short survival while the group of patients
surviving longer on average displayed an HPV16-specific
proliferation above this cut-off value after the vaccina-
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Figure 2 The group of relatively longer living patients displays a stronger HPV16-specific immune response upon vaccination. The
patients are grouped according to the median survival time (12.6 months) of the whole group. The strength (median + interquartile range) of the
indicated immune response to all 6 pools of HPV16 E6 and E7 peptides for the group of patients with survival time equal or less than
12.6 months versus that of the group of patients with a survival time beyond 12.6 months measured before vaccination (pre-vac), after 2
vaccinations (2-vac) and after the 3rd or 4th vaccination (3/4-vac) is given. Only when the strength of the immune response was significantly
different, this is indicated by the p-value.
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of proliferation was higher for the group of longer
survivors after the second (median SI = 0.6 vs SI = 1.6;
p = 0.0006) and after the last vaccination (median SI =
1.3 vs SI = 2.3; p = 0.04). Analysis of the cytokine re-
sponses revealed a pattern that reflected the proliferative
responses. The strength of IFNγ and IL-5 production
was very low in the group with relatively low survival
while in the group of longer survivors the median of
IFNγ (p < 0.0001) and IL-5 (p < 0.0001) production was
higher and increased during the vaccination period
(Additional file 5). Because of the low amounts of TNFα
and IL-10 produced, these cytokines were not analyzed
with respect to survival. Overall, it became clear that the
group of patients with cervical cancer who lived rela-
tively longer also displayed a stronger and more func-
tional vaccine-induced HPV16-specific T-cell response.Comparison of overall survival with a matched cohort
group of cervical cancer patients
Notably, the unique characteristics of immunotherapeu-
tic agents may induce cancer-specific immune responses
far before affecting tumor growth. Frequently, there is a
delayed detection of clinical activity after immunothera-
peutic treatment, and the RECIST criteria may not offer
a complete description of the response to immunothera-
peutic agents [36]. We therefore constructed an equally
sized historical control group of cervical cancer patients,
who were all treated within the LUMC and who were
matched with the vaccinated patients for a number of
clinical parameters in the following order: FIGO stage,
time to recurrence, primary treatment and salvage ther-
apy for recurrence (Additional file 6). The matched co-
hort group displayed no differences in age of diagnosis,
age of recurrence, the type of primary and salvage
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differ with respect to the site of recurrence (Additional
file 6). The loco-regional recurrences were overrepre-
sented in the matched cohort and this is known to be
associated with better survival. Indeed evaluation of
the survival after recurrence revealed a median sur-
vival of 8.5±9.4 months of the vaccinated group and
11.0±7.7 months of the matched cohort group but sur-
vival was not significantly different (p = 0.59, Wilcoxon
signed rank test). The use of the 5-year Kaplan-Meier
method and the log-rank test in order to determine
differences in overall survival showed no significant
differences (p = 0.63, log rank test; Figure 3 and
Additional file 6).
Discussion
The capacity of the HPV16-SLP vaccine to induce
HPV16-specific T-cell responses was tested in 20 pa-
tients with advanced or recurrent gynecological cancer.
Similar to our previous studies [29-32] immunotherapy
with synthetic long peptides representing the sequence
of the oncogenic proteins E6 and E7 of high risk HPV16
admixed with Montanide ISA-51 adjuvant was safe and
able to induce HPV16-specific T-cell responses. Most of
the toxicities seen did not go beyond grade II and
consisted of discomfort and low grade fever in the first
48 hours after injection. Swelling at the vaccination sites
was often graded as II. In 13 of the 16 patients who
could be evaluated immunologically an HPV16-specificvaccinated group
matched cohort
p=0.627
Figure 3 Comparison of overall survival after cervical cancer
recurrence between vaccinated patients and a matched cohort
of non-vaccinated cervical cancer patients. The survival of the
group of 16 vaccinated patients with a cervical carcinoma was
compared to a cohort group of non-vaccinated patients who where
primarily matched for FIGO stage, time to recurrence, primary
treatment and salvage therapy after recurrence and which turned
out to be matched also for age of diagnosis, age of recurrence, the
type of primary and salvage chemotherapy as well as for adjuvant
therapy. Both the log-rank and the Wilcoxon signed rank test
revealed no difference in survival between the two groups.T-cell response was induced after 2 to 4 vaccinations.
Patients who failed to mount an HPV16-specific T-cell
response also lacked robust immunity against common re-
call antigens, suggesting that they may have had a gener-
ally disease-induced decreased T cell immunocompetence,
A vaccine-induced immune response did not result in
clear regressions of the tumor according to RECIST.
Division of the patients based on the median survival
showed that the group of patients who did relatively well
also mounted a stronger immune response upon vaccin-
ation, although the vaccine-induced HPV16-specific im-
mune response was not as strong as reported for
vaccinated patients with pre-malignant VIN [31,32]. This
was also found when all patients with non-cervical car-
cinomas were excluded. It is unclear whether the correl-
ation between survival time and strength of the immune
response to HPV16 vaccination reflects a better overall
immune reactivity of patients who live longer or whether
a somewhat better vaccine-induced immune response to
HPV16 resulted in a longer survival of these patients.
Notably, of the 10 patients with a survival beyond the
median survival time of 12.6 months, 9 had received
additional therapy after recurrence or vaccine therapy,
whereas in the group of 10 patients with a relatively
lower survival time only 2 had received additional ther-
apy after recurrence indicating that the influence of add-
itional conventional therapy should also be taken into
account as a factor for better survival. In order to gain
better insight in the potential impact of vaccination on
the survival of patients with an advanced stage or recur-
rent cervical carcinoma we constructed a control cohort.
The mean and median survival time after recurrence did
not differ with that of the vaccinated cohort suggesting
that the increased strength of the vaccine-induced
HPV16-specific T-cell response observed in the group of
patients with a relatively longer survival most likely re-
flects the overall fitness of these patients but does not
add to the survival of these patients.
Previously, a group of 43 patients with end-stage cer-
vical cancer had been vaccinated with this HPV16 syn-
thetic long peptide vaccine, one of whom showed a
complete response after vaccination and 5 of whom
showed stable disease [30]. The patient with a complete
response was treated with chemo-radiation before vac-
cination, whereas 4 of the 5 cases with stable disease re-
ceived chemotherapy after vaccination. Among the long
survivors (>12.6 months) with cervical cancer (n = 8) in
the current trial, 3 had received chemotherapy prior to
vaccination and 3 received chemotherapy after vaccin-
ation. This suggests that there is no overt relation be-
tween the timing of standard therapy, before or after
immunotherapy, and clinical outcome. In addition, there
was no relation between the timing of chemotherapy,
before or after immunotherapy, and the strength of the
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chemotherapy was given months before the start of im-
munotherapy. In a few cases chemotherapy was given after
they had received 2 or more vaccinations but a negative
effect of the different types of platinum-based chemother-
apy is not to be expected as it was previously shown that
platinum-based therapy did not affect the immunogenicity
of DC vaccination [37]. However, the direct and indirect
effects of the different types of chemotherapy regimens on
the priming and function of T-cell immunity in patients
with cervical cancer should be studied in a controlled
fashion. Our recent pre-clinical data indicate synergy of
HPV long peptide vaccination and chemotherapy in effect-
ive therapy of established transplantable HPV16+ tumors
in mice (unpublished observations). Furthermore, in a
pilot study where patients with advanced cervical carcin-
oma were given a single HPV16 long peptide vaccine dose
properly timed during carboplatin and paclitaxel chemo-
therapy, revealed that a chemotherapy induced change
in myeloid cell populations coincided with a remarkably
robust induction of HPV-specific immune responses (un-
published observations). This indicates that the synergy
observed in mice may be extended to patients when proper
timing of chemotherapy and immunotherapy are taken
into account.
Conclusions
In patients with cervical cancer, several immunothera-
peutic strategies have been explored in clinical trials.
Therapeutic vaccines employing vector-based, peptide-
or protein-based, nucleic acid-based, and cell-based
therapeutic vaccines targeting the HPV16 E6 and/or E7
antigens recombinant viral vectors, have been tested
in attempts to increase the magnitude and quality of
the HPV16-specific immune responses to treat HPV16-
driven cervical cancer (reviewed in [18,28]). While we
here can conclude that the induction of HPV16-specific
immunity in patients with advanced or recurrent cer-
vical cancer patients is feasible we did not see a hint
that may indicate that this vaccine regimen may bear
clinical impact. Whereas the first results of vaccinating
patients with HPV16-induced premalignant disease are
clinically promising, it is clear that clinical improvement
by vaccination only is not likely to happen in patients with
advanced or recurrent cervical cancer probably because of
a large tumor burden and associated local immune sup-
pression which can hamper T cells to exert their full ef-
fector function However, real advances may be expected
from combination of therapeutic HPV vaccination with
carefully timed standard chemotherapy which also has
immunostimulatory properties [38]. Our unpublished
data indicate that combined therapy involving the use
of carboplatin and paclitaxel may act at least by relief of
immune suppression by myeloid cells that are presentwithin carcinoma’s [39-41]. Other attractive options for
combination with vaccination are the use of immune-
modulating compounds that polarize Th1 reactivity such
as pegylated type I interferon. We recently observed that
vaccine-induced T cell immunity was strongly improved
when vaccination was combined with IFNα in a vaccine
trial in colorectal cancer patients [42]. Improved respon-
siveness may also be achieved by a combination of the
vaccine with checkpoint control blocking antibodies such
as those blocking PD-1 as PD-1 is expressed by many cer-
vical cancer infiltrating T cells [43] and antibody-mediated
blocking of PD-1 displayed clinical success in a number of
different immunogenic cancers [44]. In addition, therapies
that deplete tumor-specific regulatory T cells which are
also present in cervical carcinoma may proof beneficial
[16,32,45,46]. It can thus be envisaged that therapeutic
efficacy will be reached by combination therapy used in
a well coordinated fashion allowing vaccine induced im-
munity to take control of the tumor.
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